Canada markets closed

ACADIA Pharmaceuticals Inc. (ACAD)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
18.49+0.29 (+1.59%)
At close: 04:00PM EDT
18.49 0.00 (0.00%)
After hours: 04:10PM EDT
Full screen
Trade prices are not sourced from all markets
Previous Close18.20
Open18.20
Bid18.44 x 100
Ask18.54 x 100
Day's Range18.05 - 18.50
52 Week Range17.56 - 33.99
Volume1,481,512
Avg. Volume1,870,432
Market Cap3.047B
Beta (5Y Monthly)0.40
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • Business Wire

    Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    SAN DIEGO, March 15, 2024--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that on March 11, 2024, the Compensation Committee of Acadia’s Board of Directors (the "Committee") granted inducement awards consisting of non-qualified stock options to purchase 8,904 shares of common stock and 5,461 restricted stock units ("RSUs") to three new employees under Acadia’s 2023 Inducement Plan. The Compensation Committee approved the awards as an inducement material to the new employees’ employme

  • Business Wire

    Acadia Pharmaceuticals to Participate in the UBS Virtual CNS Day

    SAN DIEGO, March 13, 2024--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will participate in the UBS Virtual CNS Day on Monday, March 18, 2024 at 2:00 p.m. Eastern Time.

  • Business Wire

    Acadia Pharmaceuticals Announces Top-Line Results from Phase 3 ADVANCE-2 Trial of Pimavanserin in Negative Symptoms of Schizophrenia

    SAN DIEGO, March 11, 2024--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced top-line results from the Phase 3 ADVANCE-2 trial evaluating pimavanserin for the treatment of negative symptoms of schizophrenia. Pimavanserin did not demonstrate a statistically significant improvement over placebo on the study’s primary endpoint, the change from baseline to week 26 on the Negative Symptom Assessment-16 (NSA-16) total score (-11.8 vs. -11.1; p=0.4825; effect size=0.07). The safety and tolerab